EQL Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

EQL Pharma yıllık ortalama 30.5% oranında kazançlarını artırırken, Healthcare sektöründe kazançlar growing at 20.5% annual. Gelirler growing yılda ortalama 21.6% oranında artmaktadır. EQL Pharma'in özkaynak karlılığı 15.8% ve net marjı 9.9%'dir.

Anahtar bilgiler

30.5%

Kazanç büyüme oranı

31.0%

EPS büyüme oranı

Healthcare Sektör Büyümesi	8.1%
Gelir büyüme oranı	21.6%
Özkaynak getirisi	15.8%
Net Marj	9.9%
Sonraki Kazanç Güncellemesi	05 Feb 2025

Yakın geçmiş performans güncellemeleri

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21

Recent updates

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22

Gelir ve Gider Dağılımı

EQL Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:EQL Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	316	31	77	13
30 Jun 24	291	26	74	13
31 Mar 24	264	23	71	12
31 Dec 23	246	22	68	14
30 Sep 23	256	28	64	14
30 Jun 23	270	30	63	14
31 Mar 23	260	31	60	15
31 Dec 22	403	33	59	14
30 Sep 22	440	39	56	11
30 Jun 22	419	36	51	9
31 Mar 22	410	32	48	9
31 Dec 21	233	19	41	10
30 Sep 21	145	4	34	11
30 Jun 21	117	2	31	12
31 Mar 21	179	10	28	12
31 Dec 20	172	17	32	2
30 Sep 20	163	16	32	2
30 Jun 20	157	14	32	2
31 Mar 20	72	3	30	0
31 Dec 19	68	2	24	5
30 Sep 19	58	-2	25	3
30 Jun 19	54	-2	25	2
31 Mar 19	50	-2	25	0
31 Dec 18	43	-2	21	0
30 Sep 18	41	0	20	0
30 Jun 18	35	0	18	0
31 Mar 18	32	-1	17	0
31 Dec 17	30	1	16	0
30 Sep 17	30	0	15	0
30 Jun 17	26	0	15	0
31 Mar 17	24	0	14	0
31 Dec 16	31	4	15	0
30 Sep 16	29	5	14	0
30 Jun 16	34	6	14	0
31 Mar 16	35	7	14	0
31 Dec 15	29	4	13	0
30 Sep 15	26	1	13	0
30 Jun 15	21	-2	13	0
31 Mar 15	19	-5	13	0
31 Dec 14	18	-9	13	0
30 Sep 14	19	-11	13	0
30 Jun 14	19	-12	12	0
31 Mar 14	20	-11	11	0
31 Dec 13	22	-8	10	0

Kaliteli Kazançlar: EQL yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: EQL 'nin mevcut net kar marjları (9.9%) geçen yılın (10.8%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: EQL son 5 yılda karlı hale geldi ve kazançlarını yıllık 30.5% oranında artırdı.

Büyüme Hızlandırma: EQL 'un son bir yıldaki kazanç büyümesi ( 13.1% ) 5 yıllık ortalamasının ( 30.5% /yıl) altındadır.

Kazançlar vs. Sektör: EQL geçen yılki kazanç büyümesi ( 13.1% ) Healthcare sektörünün 29.5% performansını geride bırakmadı.

Özkaynak Getirisi

Yüksek ROE: EQL 'nin Özsermaye Getirisi ( 15.8% ) düşük olarak değerlendiriliyor.

EQL Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025

First quarter 2025 earnings: Revenues exceed analyst expectations

Full year 2024 earnings: EPS and revenues miss analyst expectations

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Chief Operating Officer recently bought kr281k worth of stock

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board Member

EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

First quarter 2025 earnings: Revenues exceed analyst expectations

EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024

EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in Switzerland

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Investor sentiment improves as stock rises 16%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings released

Insufficient new directors

Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023)

EQL Pharma AB (publ) to Report Fiscal Year 2024 Results on May 14, 2024

New major risk - Earnings quality

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023

EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Founder & Chairman recently sold kr11m worth of stock

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022)

EQL Pharma AB (publ) Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One Step

First quarter 2023 earnings released

EQL Pharma AB (publ) Announces Executive Changes

EQL Pharma AB (publ) to Report Q3, 2023 Results on Feb 14, 2023

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021)

EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/Ml from Danish Medicines Agency

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

EQL Pharma AB (publ) to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020)

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

EQL Pharma AB (Publ) Announces Approval of Mellozzan (Melatonin)

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Third quarter 2021 earnings released

EQL Pharma AB (Publ) Convenes Nomination Committee

EQL Pharma Announces Approval of Glucosparc (Metformin)

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

New 90-day high: kr40.00

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: kr33.50

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Director recently sold kr285k worth of stock

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

EQL Pharma Receives a New Order for Consumables from a Hospital Region

Director recently sold kr2.8m worth of stock

Market bids up stock over the past week

Market pulls back on stock over the past week